PERSPECTA

News from every angle

← Back to headlines

Immunity Bio Addresses FDA Concerns Regarding Anktiva Marketing

Immunity Bio has issued a response to the Food and Drug Administration's concerns regarding the marketing materials for its product, Anktiva.

6 Apr, 12:36 — 6 Apr, 12:36
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed5d ago

Immunity Bio responds to FDA concerns over Anktiva marketing materials

Read full article →

Related Stories

Amazon's First Customer Receipt Goes Viral, Bezos and Musk React

just now

Four Arrested for Selling P102 Million in Counterfeit Anti-Cancer Medicine in Makati

just now

Philippines receives diesel shipment from Malaysia

just now

DPWH Vows Completion of Stalled Laguna Medical Center Building by 2027

7m ago